Bradykinin analogs as selective inhibitors of cell activation

Details Bradykinin analogs as selective inhibitors of cell activation Bradykinin analogs as selective inhibitors of cell activation

2006-01-03

2006-01-03

Campell, Bruce R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S013800, C514S014800, C514S015800, C514S016700, C514S017400, C514S018700, C530S324000, C530S325000, C530S326000, C530S327000, C530S328000, C530S329000

Reexamination Certificate

active

06982249

ABSTRACT:
The present invention provides bradykinin peptide analogs, compositions, and methods of inhibiting thrombin-induced platelet and other cell activation. The bradykinin analogs comprise single or multiple peptide segments. The invention also provides a method for identifying compounds that selectively inhibit thrombin-induced platelet and other cell activation.

REFERENCES:
patent: 4585757 (1986-04-01), Pang et al.
patent: 4638047 (1987-01-01), Szelke et al.
patent: 4693993 (1987-09-01), Stewart et al.
patent: 4870017 (1989-09-01), Ben-Bassat et al.
patent: 4923963 (1990-05-01), Stewart et al.
patent: 5231080 (1993-07-01), Scholkens
patent: 5300490 (1994-04-01), Kunihiro et al.
patent: 5350578 (1994-09-01), Griffin et al.
patent: 5385889 (1995-01-01), Kyle et al.
patent: 5409899 (1995-04-01), Fauchere et al.
patent: 5416191 (1995-05-01), Cheronis et al.
patent: 5446131 (1995-08-01), Maraganore
patent: 5472945 (1995-12-01), Schmaier et al.
patent: 5489575 (1996-02-01), Lee et al.
patent: 5607676 (1997-03-01), Gevas et al.
patent: B-39431/89 (1990-05-01), None
patent: WO 92/17201 (1991-10-01), None
patent: WO 94/11021 (1994-05-01), None
patent: WO/96/41640 (1996-12-01), None
Websters II, New Riverside University Dictionary 1259 (Anne H. Soukhanov ed., The Riverside Publishing Co. 1984).
Stewart et al., “Bradykinin Chemistry: Agonists and Antagonists”. In: Advance in Experimental Medicine and Biology,New York: Plenum Press, p. 585-589 (1983).
Martin et al., “Bradykinin Stimulates Phosphodiesteratic Cleavage of Phosphatidylcholine in Cultured Endothelial Cells”,Biochemical and Biophysical Research Communication, 157(3): 1271-1279 (1988).
Chem abstr., vol. 107, No. 17, Oct. 26, 1987 (Columbus, Ohio), p. 146, column 2, the abstract No. 148141v, Alheid et al., “Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets.”Thromb Res., 47(5): 561-71 (1987).
Chem. abstr., vol. 84, No. 21, May 24, 1976 (Colombus. Ohio), p. 417, column 2, the abstract No. 148985e, Shikawa et al., “Prostaglandin synthetase activity and hormone responsiveness in normal and SV40 transformed WI-38 fibroblasts”,J. of Cyclin Nucleotide Res., 2(2): 115-28 (1976).
Database CAplus on STN, Chemical Abstracts Service, (Columbus, OH), CAplus No. 1996:519830,Hasanet al., “Brandykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation”, abstract Circulation 1996.
Chem. abstr., vol. 111, No. 9, Aug. 28, 1989 (Columbus, Ohio), p. 178, column 2, the abstract No. 71858g, Loeb et al., “Endotherlium-dependent potentiation of human platelet aggregation”,Thromb. Res., 54(5): 477-86 (1989).
Chem. abstr., vol. 93, No. 25, Dec. 22, 1980 (Columbus Ohio), p. 100, column 1, the abstract No. 231243t, Imai et al., “Effects of prostacyclin on platelet aggregation as studied with ‘filter-loop’ technique in the flowing blood of the dog”,Artery, 8(1): 90-5 (1980).
Ngo et al., “Computational Complexity Protein Structure Problem and the Levinthal Paradox”,The Protein Folding Prediction and Tertiary Structure Prediction, pp. 491-495 (1994).
Hasan, et al., “The Carboxyl Terminus of Bradykinin and Amino Terminus of the Light Chain of Kininogens Comprise and Endothelial Cell Binding Domain”,The Journal of Biological Chemistry, 269(50): 31822-31830 (Dec. 16, 1994).
Wirth, et al., “Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies”,British Journal of Pharmacology, 102(3): 774-777 (Mar., 1991).
Vu, et al., “Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Protelytic Mechanism of Receptor Activation”,Cell, 64: 1057-1068 (Mar. 22, 1991).
Puri, et al., “Inhibition of Thrombin-Induced Platelet Aggregation By High Molecular Weight Kininogen”,Transactions of the Association of American Physicans, C: 232-240 (1987).
Puri, et al., “Cleavage of A 100 kDa Membrane Protein (Aggregin) During Thrombin-Induced Platelet Aggregation Is Mediated By The High Affinity Thrombin Receptors”,Biochemical and Biophysical Research Communications, 162(3): 1017-1024 (Aug. 15, 1989).
Puri, et al., “Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation”,Blood Coagulation and Fibrinolysis, 4: 465-478 (1993).
Puri, et al., “High Molecular Weight Kininogen Inhibits Thrombin-Induced Platelet Aggregation and Cleavage of Aggregin by Inhibiting Binding of Thrombin to Platelets”,Blood, 77(3): 500-507 (Feb. 1, 1991).
Meloni, et al., “Low Molecular Weight Kininogen Binds to Platelets to Modulate Thrombin-Induced Platelet Activation”,The Journal of Biological Chemistry, 265(11): 6786-6794 (Apr. 13, 1991).
Hasan et al., “Bradykinin And Related Peptides Selectively Inhibit α-Thrombin's Ability To Activate The Platelet Thrombin Receptor”,Thrombosis and Haemostasis, 73(6): 94 (Abstract) (Jun., 1995).
Imai, et al. “Effects of Prostacyclin on Plateet Aggregation as Studied With “Filter Loop” Technique in the Flowying of Blood of the Dog”,Artery8(1): 63-72 (1980).
J.A. Parsons, “Peptide Hormones”, published 1976 by University park Press (Baltimore), p. 1-7.
Park et al., “Synthesis of Peptides by the Solid Phase Method, III. Bradykinin: Fragments and Analogs”,Can. J. Biochem., 56: 92-100 (1978).
Hasan et al., “Bradykinin and Its Metabolite, Arg-Pro-Pro-Gly-Phe, Are Selective Inhibitors of α-Thrombin-Induced Platelet Activation”,Circulation, 94(3): 517-528 (Aug 1, 1996).

Affiliated with

Also associated with

Rating

Bradykinin analogs as selective inhibitors of cell activation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bradykinin analogs as selective inhibitors of cell activation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bradykinin analogs as selective inhibitors of cell activation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3580708